Trends in Use of Medications for Opioid Use Disorder among Commercially Insured U.S. Surgical Patients, 2016 to 2022
Authors' conclusion
In this cohort study of surgical procedures among privately insured U.S. adults, the prevalence of MOUD use increased between 2016 and 2022
Study context
- Population
- Commercially insured US adults 18 to 64 yr undergoing 1 of 1,083 major surgical procedures, 2016 to 2022
- Participants
- 5,013,213 participants · 8,137,973 surgical admissions
- Outcome
- Annual change in prevalence of MOUD use 1 to 180 days before surgery
Methodological detailsclaims database (Merative MarketScan Commercial Database), adjusted logistic regression
- Claims database (Merative MarketScan Commercial Database)
- Adjusted logistic regression
Main finding
As reported in the abstract
Adjusted prevalence of MOUD use
Adjusted prevalence of medications for opioid use disorder (MOUD) use, 2016 (per 100,000)
55.2
Adjusted prevalence of MOUD use, 2022 (per 100,000)
99.8
Adjusted annual change
16.9
per 100,000 procedures; 95% CI 14.0 to 19.8
Observational data: associations, not effects.
Further findings
Type of MOUD among 15,701 surgical admissions for patients using MOUD · 2016 to 2022
- Buprenorphine (13,193)
- 84.0%
Procedures with highest rate of MOUD use (per 100,000 procedures) · 2016 to 2022
- Debridement
- 719.0
- Shoulder arthroplasty
- 579.4
- Lower extremity amputation
- 529.6
- Hip or pelvis open fracture repair
- 497.6
Original publication
Trends in Use of Medications for Opioid Use Disorder among Commercially Insured U.S. Surgical Patients, 2016 to 2022. Anesthesiology. Published 25 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →